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ABSTRACT 
 
The 1-phenyl-1-(quinazolin-4-yl) ethanol compounds are alkaloids of quinozoline class 
found in many Hydrangeaceae families. A survey revealed that most of the identified quinazoline 
derivatives have anticancer activity. Toxicity prediction of 1-phenyl-1-(quinazolin-4-yl) ethanols 
compounds were performed to obtain the best three compounds with high activity and the lowest 
toxicity. Toxicity prediction was conducted using Toxtree, pkCSM and PreADMET. The 2D 
structure of compounds were formed using ChemDraw. The decision tree approach was used in 
Toxtree application with endpoints including Cramer rules, Kroes TTC, carcinogenicity (genotoxic 
and non genotoxic) and in vitro mutagenicity. Graph based signature was used in pkCSM 
application with endpoints including mutagenicity, maximum daily dose, LD50 and hepatotoxicity. 
In PreADMET application, a method based on drugs similarity and ADMET properties was used 
with endpoints including mutagenicity, carcinogenicity to rat and mice. The results of data analysis 
showed that the best three anticancer compounds that have high activity and the lowest toxicity are 
compounds 14, 16 and 19. 
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INTRODUCTION  
Cancer is a chronic disease that causes death number two in the world. In 2012, cancer is 
responsible for the deaths of around 8.2 million people worldwide. The cases of cancer can 
increase up to 50% in 2020 (Parameshwar et al., 2016). The high number of deaths caused by 
cancer led to studies on anticancer compounds expand. 
The 1-phenyl-1-(quinazolin-4-yl) ethanol compounds are alkaloids of quinazolin group 
which are widely present in Hydrangeaceae family (Ajani et al., 2016). The most of quinazolin 
derivatives have been identified as having biological activities such as anticancer, antioxidant, 
antiviral, anticonvulsant, antiinflammatory, antituberculous, anti-HIV, analgesic, and antimicrobial 
(Faraj et al., 2014). Kuroiwa et al. (2015) have conducted a Quantitative Structure and Activity 
Relationships (QSAR) study and in vitro testing of 1-phenyl-1-(quinazolin-4-yl) ethanol 
compounds. The in vitro testing result of cell line A549 (lung) obtained a value of biological 
activity of IC50 which showed that 1-phenyl-1-(quinazolin-4-yl) ethanol compounds have potential 
as anticancer. The compounds have an anticancer mechanism through the binding of tubulin which 
binds to colchicine. It inhibits the binding of tubulin molecule and microtubule resulting 
polymerization in microtubules or failure of microtubule formation in cancer cells. 
In silico toxicity prediction is a type of toxicity assessment using computational resources 
(algorithms, softwares and data) to organize, analyze, modeling, simulate, visualize, or predict 
chemical toxicity (Raies and Bajic, 2016). In silico toxicity prediction of 1-phenyl-1-(quinazolin-4-
yl) ethanol compounds was performed using Toxtree, pkCSM, and preADMET.  
Toxtree is designed to estimate toxic hazards using decision tree approach. Decision tree 
uses the method based on Structural Alerts (SA) and QSAR. The method has a role to designate the 
potential of toxic chemicals (Benigni et al., 2008). The performance of Toxtree in the external 
validation dataset showed an accuracy of 70% and a sensitivity of 78.3% in the carcinogenicity test 
and an accuracy of 78% for the mutagenicity test (Valerio, 2009). Toxtree represents endpoints of 
different toxicities, i.e. Cramer rule, Kroes TTC, carcinogenicity (genotoxic and non genotoxic) 
and in vitro mutagenicity (Ames test). 
PkCSM (Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-
Based Signatures) is a method for predicting and optimizing pharmacokinetic properties and 
toxicity properties. It use graph-based signatures approach. pkCSM adapted the cut off scanning 
concept to develop a predictive model of ADMET (Absorption, Distribution, Metabolism, 
Excretion, Toxicity) properties for drug development. The performance of pkCSM software in the 
external validation dataset showed an accuracy of 83.8% in the mutagenicity test. There are several 
endpoints of pkCSM i.e. LD50, ames test, maximum daily dose, and hepatotoxic (Pires et al., 2015). 
PreADMET (Prediction of ADME/Tox) developed a fast and reliable method to predict the 
similarity of drugs and ADMET properties. This application can calculate more than 900 molecular 
descriptors including constitutional, topological, electrostatic, physico-chemical and geometric 
descriptor to predict ADME (Absorption, Distribution, Metabolism, Excretion) properties. 
PreADMET collects databases containing ADME and toxicities data to train physiologically-based 
pharmacokinetics model tissues and toxicity predictions. PreADMET provided 62.5% accuracy and 
52.2% sensitivity for carcinogenicity test (Zhang et al., 2017). PreadMET predicts toxicity based 
on Ames mutagenity parameters. The actual value of the prediction is "positive" or "negative". The 
carcinogenicity is predicted based on the structure results which is constructed from NTP (National 
Toxicology Program) data and US FDA (US Food and Administration). It is the result of in vivo 
carcinogenicity test in rat for two years (Riju et al., 2010). 
Many of bioactive compounds have been shown anticancer activity but their utilization is 
limited due to their side effects and high toxic effects, that are very dangerous and life-threatening 
effect (Priyanto, 2015). Therefore, in silico toxicity prediction of 1-phenyl-1-(quinazolin-4-yl) 
ethanol compounds was performed before in vitro and in vivo testing to minimize the number of 
test compounds and test animals in the following tests. 
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MATERIALS AND METHODS 
Materials 
The softwares used in this research were ChemDraw 2016 (http: 
//scistore.cambridgesoft.com/) (License Code: 338-284099-4415), Openbabel GUI 2.4.1 
(https://sourceforge.net), pkCSM ( http://biosig.unimelb.edu.au/pkcsm), Toxtree version 2.6.6 
(http: //toxtree.sourceforge. net /) and preADMET (http://preadmet.bmdrs.kr). The materials used 
in this research were the 2D structures and IC50 value of 44 compounds of 1-phenyl-1-(quinazolin-
4-yl) ethanol which have been synthesized by Kuroiwa et al., (2015).  IC50 value of 1-phenyl-1-
(quinazolin-4-yl) ethanol compounds are presented in Table I. 
 
Table I. IC50 of 1-phenyl-1-(quinazolin-4-yl) ethanol compounds (Kuroiwa et al., 2015)  
  
Compound 
Number 
Name of The 
Compounds 
IC50 
(µM) 
Compound 
Number 
Name of The  
Compounds 
IC50  
(µM) 
1a 1-(4-
methoxyphenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
0.27 9 1-(2-
chloroquinazolin-4-
yl)-1-(4-
methoxyphenyl)ethan
-1-ol 
2.0 
1b 1-(4-fluorophenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
>25 14 1-(4-
methoxyphenyl)-1-
(2-methylquinazolin-
4-yl)ethan-1-ol 
0.053 
1c 1-(4-chlorophenyl)-
1-(quinazolin-4-
yl)ethan-1-ol 
>25 15 1-(2-
cyclohexylquinazolin
-4-yl)-1-(4-
methoxyphenyl)etha
n-1-ol 
0.1 
1d 1-(quinazolin-4-yl)-
1-(4-
(trifluoromethyl)phen
yl)ethan-1-ol 
>25 16 1-(4-
methoxyphenyl)-1-
(2-
(trichloromethyl)quin
azolin-4-yl)ethan-1-
ol 
0.038 
1f 1-(4-ethoxyphenyl)-
1-(quinazolin-4-
yl)ethan-1-ol 
0.30 17 1-(2-
chloroquinazolin-4-
yl)-1-(4-
methoxyphenyl)etha
n-1-ol 
0.027 
1g 1-(4-(tert-
butoxy)phenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
>25 18 (R)-4-(1-hydroxy-1-
(4-
methoxyphenyl)ethyl
)quinazolin-2(1H)-
one 
>25 
1h 1-(quinazolin-4-yl)-
1-(4-
(trifluoromethoxy)ph
enyl)ethan-1-ol 
>25 19 (R)-1-(4-
methoxyphenyl)-1-
(2-
methoxyquinazolin-
4-yl)ethanol 
0.058 
1i 1-(3-
methoxyphenyl)-1-
>25 20 (R)-1-(2-
ethoxyquinazolin-4-
0.34 
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Compound 
Number 
Name of The 
Compounds 
IC50 
(µM) 
Compound 
Number 
Name of The  
Compounds 
IC50  
(µM) 
(quinazolin-4-
yl)ethan-1-ol 
yl)-1-(4-
methoxyphenyl)etha
nol 
1j 1-(3,4-
bis(methoxymethoxy
)phenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
20 21 (R)-1-(4-
methoxyphenyl)-1-
(2-
propoxyquinazolin-
4-yl)ethanol 
1.2 
1k 
 
1-(3,4-
dimethoxyphenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
21 22 1-(2-
(allyloxy)quinazolin-
4-yl)-1-(4-
methoxyphenyl)etha
n-1-ol 
0.41 
1l 1-(quinazolin-4-yl)-
1-(3,4,5-
trimethoxyphenyl)eth
an-1-ol 
>25 23 (R)-1-(2-
(cyclohexyloxy)quin
azolin-4-yl)-1-(4-
methoxyphenyl)etha
nol 
3.3 
1m 1-(3-
(benzyloxy)phenyl)-
1-(quinazolin-4-
yl)ethan-1-ol 
>25 24 (R)-1-(4-
methoxyphenyl)-1-
(2-
methoxyquinazolin-
4-yl)ethanol 
0.067 
1n 3-(1-hydroxy-1-
(quinazolin-4-
yl)ethyl)phenol 
>25 25 (R)-1-(2-
(dimethylamino)quin
azolin-4-yl)-1-(4-
methoxyphenyl)etha
nol 
0.21 
1o 1-(4-
(methylamino)phenyl
)-1-(quinazolin-4-
yl)ethan-1-ol 
4.1 26 (R)-1-(2-
(cyclohexylamino)qu
inazolin-4-yl)-1-(4-
methoxyphenyl)etha
nol 
2.7 
1p 1-(4-
(dimethylamino)phen
yl)-1-(quinazolin-4-
yl)ethan-1-ol 
1.3 27 (R)-1-(4-
methoxyphenyl)-1-
(2-(piperidin-1-
yl)quinazolin-4-
yl)ethanol 
2.7 
1q 1-(4-
(methylthio)phenyl)-
1-(quinazolin-4-
yl)ethan-1-ol 
0.34 28 (R)-1-(4-
methoxyphenyl)-1-
(2-(4-
methylpiperazin-1-
yl)quinazolin-4-
yl)ethanol 
19 
4a (4-
methoxyphenyl)(quin
azolin-4-
yl)methanone 
20 29 (R)-1-(4-
methoxyphenyl)-1-
(2-
morpholinoquinazoli
0.17 
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Compound 
Number 
Name of The 
Compounds 
IC50 
(µM) 
Compound 
Number 
Name of The  
Compounds 
IC50  
(µM) 
n-4-yl)ethanol 
4f (4-
ethoxyphenyl)(quina
zolin-4-yl)methanone 
>25 30 (R)-1-(2-(4-(4-
fluorophenyl)piperaz
in-1-yl)quinazolin-4-
yl)-1-(4-
methoxyphenyl)etha
nol 
1.9 
5 1-(4-
methoxyphenyl)-1-
(quinazolin-4-
yl)propan-1-ol 
1.8 31 (1R)-1-(4-
methoxyphenyl)-1-
(2-(thiophen-3-
yl)quinazolin-4-
yl)ethanol 
0.035 
6 (4-
methoxyphenyl)(phe
nyl)(quinazolin-4-
yl)methanol 
9.8 32 (R)-1-(2-(4-
chlorophenyl)quinaz
olin-4-yl)-1-(4-
methoxyphenyl)etha
nol 
0.40 
7 2,2,2-trifluoro-1-(4-
methoxyphenyl)-1-
(quinazolin-4-
yl)ethan-1-ol 
1.1 33 1-(2-(2-
chlorophenyl)quinaz
olin-4-yl)-1-(4-
methoxyphenyl)etha
n-1-ol 
0.78 
8 (4-
methoxyphenyl)(quin
azolin-4-yl)methanol 
>25 34 1-(2-(3-
chlorophenyl)quinaz
olin-4-yl)-1-(4-
methoxyphenyl)etha
n-1-ol 
2.1 
 
Methods 
The 2D structures of 44 compounds of 1-phenyl-1-(quinazolin-4-yl) ethanol were prepared 
using ChemDraw 2016. The 1-phenyl-1-(quinazoline-4-yl) ethanol compounds were screened 
using pkCSM to find out whether the compounds conform the Lipinski's rule of Five. The 
unconform compounds  maximum 2 endpoints of Lipinski's rule of Five were eliminated. The 
toxicity of screened 1-phenyl-1-(quinazolin-4-yl) ethanol compound were predicted using Toxtree, 
pkCSM and PreADMET. The endpoints selected in Toxtree were Cramer rule, Kroes TTC decision 
tree, carcinogenicity (genotox and non genotox) mutagenicity rule base by ISS, and in vitro 
mutagenicity (Ames test) alerts by ISS. Open Babel GUI is used in pkCSM to create a compound 
SMILE format. The selected endpoint in pkCSM were Ames Toxicity, Maximum Tolerated Dose, 
Rat Acute Oral Toxicity (LD50) and hepatotoxicity. The selected endpoints in PreADMET were 
Ames Test and Rodent Carcinogenicity (Mice and Rat). 
 
Data Analysis 
The toxicity prediction results of 1-phenyl-1-(quinazolin-4-yl) ethanol compounds were 
quantitative and qualitative data. Qualitative data were expressed in positive and negative 
statements. Then made in the form of scoring, where the positive toxic score was 1 and negative 
toxic scored was 2. The data analysis used the scoring model by summing all endpoints of Toxtree, 
pkCSM and PreADMET to obtain five compounds with the lowest toxicity effect (largest score). 
Then five of 1-phenyl-1-(quinazolin-4-yl) ethanol compounds which have high activity based on in 
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vitro test of Kuroiwa et al. (2015) against cell line A549 (lung) were selected. The best compound 
is obtained through the selected scoring model by comparing any compounds having a low toxic 
effect and followed by the most amount of toxic negative endpoints. The next step for getting the 
three compounds that have the highest activity with the lowest toxicity was comparing the highest 
scores and the smallest IC50 values among the five compounds. 
 
RESULTS AND DISCUSSION 
Lipinski's rule of five calculations 
The Lipinski's rule of five calculations were performed to determine the degree of absorption 
or permeability of compounds against lipid bilayers in the human body. The Lipinski rule is a 
parameter that demonstrates the oral bioavailability of a compound. Good bioavailability will 
satisfy the Lipinski rule where the maximum molecular weight of the compound is 500, the log P is 
not greater than 5, the hydrogen bond donor is less than 5, and hydrogen bond acceptor is less than 
10 (Lipinski et al., 2012). The results of Lipinski's rule of Five calculations using pkCSM are 
presented in Table II. 
 
Table II. Results of Lipinski’s Rule of Five calculation 
 
Compound 
Number 
Molecular 
Weight 
Log P 
Hydrogen 
Bonds Acceptor 
Hydrogen 
Bonds 
Donor 
1a 280.327 2.8942 4 1 
1b 268.291 3.0247 3 1 
1c 284.746 3.5390 3 1 
1d 318.298 3.9044 3 1 
1f 294.354 3.2843 4 1 
1g 322.408 4.0629 4 1 
1h 334.297 3.7842 4 1 
1i 280.327 2.8942 4 1 
1j 370.405 2.8510 7 1 
1k 310.353 2.9028 5 1 
1l 342.351 1.8413 7 2 
1m 356.425 4.4646 4 1 
1n 266.300 2.5912 4 2 
1o 295.386 3.5634 4 2 
1p 293.370 2.9516 4 1 
1q 296.395 3.6075 4 1 
4a 264.284 2.8694 4 0 
4f 278.311 3.2595 4 0 
5 294.354 3.2843 4 1 
6 294.354 3.2843 4 1 
7 334.297 3.4366 4 1 
8 266.300 2.7201 4 1 
9 310.353 2.9028 5 1 
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Compound 
Number 
Molecular 
Weight 
Log P 
Hydrogen 
Bonds Acceptor 
Hydrogen 
Bonds 
Donor 
14 294.354 3.2026 4 1 
15 362.473 4.9419 4 1 
16 397.689 4.7209 4 1 
17 314.772 3.5476 4 1 
18 296.326 2.1875 4 2 
19 310.353 2.9028 5 1 
20 324.380 3.2929 5 1 
21 338.407 3.6830 5 1 
22 352.434 4.0951 5 1 
23 378.472 4.6057 5 1 
24 326.421 3.6161 5 1 
25 323.396 2.9602 5 1 
26 377.488 4.6388 5 2 
27 363.461 3.8845 5 1 
28 378.476 2.6460 6 1 
29 365.433 2.7308 6 1 
30 458.537 4.3599 6 1 
31 362.454 4.6227 5 1 
32 390.870 5.2146 4 1 
33 390.870 5.2146 4 1 
34 390.870 5.2146 4 1 
 
Based on results of Lipinski's Rule of Five calculations, all of 1-phenyl-1-(quinazolin-4-yl) 
ethanol compounds conform Lipinski's rule. All compounds were predicted having good 
absorptivity for an oral medication (Wulandari and Kristin, 2010). Based on research conducted by 
Veber et al. (2002) concluded that a compound with lower molecular weight, log P, hydrogen bond 
donor, and hydrogen bond acceptor has the higher bioavailability. 
 
Toxicity predictions 
The results of toxicity prediction by Toxtree, pkCSM and PreADMET are presented in Table 
III. 
 
 
Table III. Results of toxicity prediction by Toxtree, pkCSM and PreADMET 
 
Compound 
Number 
A B C D E F G H I J K L Scoring 
1a 1 1 2 2 2 2 1.273 2.079 2 1 2 2 20.352 
1b 1 1 2 1 2 1 1.330 2.016 2 1 1 2 17.346 
1c 1 1 2 2 2 1 1.225 1.973 2 2 1 2 19.198 
1d 1 1 2 2 2 2 1.072 2.223 1 2 1 2 19.295 
1f 1 1 2 2 2 1 2.323 1.870 2 1 2 2 20.193 
1g 1 1 2 2 2 2 -1.119 2.007 1 2 2 2 17.888 
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Compound 
Number 
A B C D E F G H I J K L Scoring 
1h 1 1 2 2 2 2 -1.127 2.295 2 1 2 2 18.168 
1i 1 1 2 2 2 2 1.849 1.834 2 1 1 2 19.683 
1j 1 1 2 2 2 2 3.034 2.204 2 2 2 2 23.238 
1k 1 1 2 2 2 2 1.766 2.269 1 2 2 2 21.035 
1l 1 1 2 2 2 2 2.265 1.906 1 2 2 2 21.171 
1m 1 1 2 2 2 1 2.265 2.466 1 1 1 2 18.731 
1n 1 1 2 2 2 2 1.442 2.147 2 1 1 2 19.589 
1o 1 2 1 2 1 2 1.528 2.367 2 2 1 2 19.895 
1p 1 2 1 2 1 2 1.442 2.147 2 2 1 2 19.589 
1q 1 1 2 2 2 2 2.094 1.804 2 1 1 2 19.898 
4a 1 1 2 2 2 2 1.879 2.294 2 1 2 2 21.173 
4f 1 1 2 2 2 1 4.188 2.245 2 1 2 2 22.433 
5 1 1 2 2 2 2 1.227 2.116 2 2 2 2 21.343 
6 1 1 2 2 2 1 2.275 2.996 1 2 2 2 21.271 
7 1 1 2 2 2 2 1.259 2.275 2 1 2 2 20.534 
8 1 1 2 2 2 2 1.164 1.980 2 1 2 2 20.144 
9 1 1 2 2 2 2 2.565 2.525 1 2 2 2 22.090 
14 1 1 2 2 2 2 1.361 2.525 2 2 2 2 21.886 
15 1 1 2 1 2 2 -1.349 2.179 1 2 2 2 16.830 
16 1 1 2 2 2 2 1.432 2.641 2 2 2 2 22.073 
17 1 1 2 2 2 2 1.208 2.270 1 2 2 2 20.478 
18 1 1 2 2 2 2 2.005 2.139 2 1 1 2 20.144 
19 1 1 2 2 2 2 1.503 2.189 2 2 2 2 21.692 
20 1 1 2 2 2 2 1.496 2.237 1 2 2 2 20.733 
21 1 1 2 2 2 2 3.169 2.091 1 2 2 2 22.260 
22 1 1 2 2 2 2 2.606 2.231 2 1 2 2 21.837 
23 1 1 2 2 2 2 1.334 2.472 1 2 2 2 20.806 
24 1 1 1 2 2 2 1.337 2.170 2 2 2 2 20.507 
25 1 2 1 2 1 2 1.170 2.141 1 2 2 2 19.311 
26 1 1 2 2 2 2 -1.462 2.539 1 2 2 2 18.077 
27 1 1 2 2 2 2 -1.459 2.326 1 2 2 2 17.867 
28 1 1 2 2 2 2 1.288 2.617 1 2 1 2 19.905 
29 1 1 2 2 2 2 -1.049 2.245 1 2 2 2 18.196 
30 1 1 2 2 2 2 1.119 2.541 1 2 2 2 20.660 
31 1 1 2 1 2 1 2.512 2.289 1 2 2 2 19.801 
32 1 1 2 1 2 1 2.576 2.397 1 2 2 2 19.973 
33 1 1 2 1 2 1 2.600 2.424 1 2 2 2 20.024 
34 1 1 2 1 2 1 2.431 2.431 1 2 2 2 16.862 
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Information: 
1= Positive toxic 
2= Negative toxic 
G= Maximum daily dose pkCSM 
 (mg/kg/day) 
A= Cramer rule Toxtree  
B= Kroes TTC Toxtree  
H= Rat Acute Oral Toxicity (LD50) pkCSM  
 (mol/kg) 
C= Carcinogenicity genotox Toxtree  
D= Carcinogenicity non genotox Toxtree 
I=  Hepatotoxicity pkCSM 
J= Mutagenicity (Ames Test) PreADMET 
E= In vitro mutagenicity (Ames test) Toxtree K= Carcinogenicity to rat PreADMET 
F= Mutagenicity (Ames test) pkCSM L= Carcinogenicity to mice PreADMET 
 
Table IV. Classification of the compounds based on their toxicity 
 
Toxicity Compound 
High toxicity risk (Cramer 
rules Toxtree) 
1a, 1b, 1c, 1d, 1f, 1g, 1h, 1i, 1j, 1k, 1l, 1m, 1n, 1o, 1p, 1q, 4a, 4f, 5, 6, 
7, 8, 9, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 
30, 31, 32, 33 and 34 
High toxicity risk (Kroes 
TTC Toxtree) 
1a, 1b, 1c, 1d, 1f, 1g, 1h, 1i, 1j, 1k, 1l, 1m, 1n, 1q, 4a, 4f, 5, 6, 7, 8, 9, 
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33 
and 34 
Carcinogen genotox 
Toxtree 
1o, 1p, 24 and 25 
Carcinogen non genotox 
Toxtree 
1b, 31, 32, 33 and 34 
In vitro mutagen (Ames 
test) Toxtree 
1o, 1p, 25 and 26 
Mutagen (Ames test) 
pkCSM 
1b, 1c, 1f, 1m, 4f, 6, 31, 32, 33 and 34 
The lowest maximum 
daily dose pkCSM 
26 
The lowest rat acute oral 
toxicity (LD50) pkCSM 
1q 
Hepatotoxic pkCSM 1d, 1g, 1k, 1l, 1m, 6, 9, 15, 17, 20, 21, 23, 25, 26, 27, 28, 29, 30, 31, 
32, 33 and 34 
Mutagen (Ames Test) 
PreADMET 
1a, 1b, 1f, 1h, 1i, 1m, 1n, 1q, 4a, 4f, 7, 8, 18 and 22 
Carcinogen to rat 
PreADMET 
1b, 1c, 1d, 1i, 1m, 1n, 1o, 1p, 1q, 18 and 28 
 
According to Table III and Table IV, in the Cramer rule Toxtree, all of 1-phenyl-1-
(quinazolin-4-yl) ethanol compound derivatives are class 3 (score 1) which have a high toxicity 
risk. It means the high concentrations of the 1-phenyl-1-(quinazolin-4-yl) ethanol compounds are 
not guaranteed for the safety in their use. Based on the Kroes TTC endpoint, 41 compounds are 
positively at high risk bacause their exposure limits more than 0.15 μg/day (score 1). While 
compounds 1o, 1p, and 25 have no a significant risks (score 2). The risk can be reduced if given at 
or below 0.15 μg/day with a threshold value of 86-97%. Based on the predictions of 
carcinogenicity (genotoxic and non genotoxic), compounds 1o, 1p, 24, and 25 are genotoxic 
carcinogenic (score 1) whereas compounds 1b, 31, 32, 33, and 34 are non-genotoxic carcinogenic 
(score 1). Genotoxic carcinogens cause irreversible genetic damage or mutations by binding to 
DNA. Non-genotoxic carcinogens or epigenetics not bind covalently to DNA do not cause DNA 
damage directly and generally negative for mutagenicity tests. Based on in vitro mutagenicity 
(Ames test) predictions, compounds 1o, 1p, 25, and 26 have risk as mutagen (score 1), while 40 
other compounds have no risk as mutagen (score 2). 
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Compound 6 has the highest value of LD50 endpoint of 2.996 mol/kg. Compound 4f has the 
highest value at the maximum daily dose endpoint of 4.188 mg/kg/day. The higher maximum daily 
dose and LD50 value in the acute toxicity test of the compound, the compound will not have toxic 
effect on the mice. Based on the mutagenicity endpoint of pKCSM, the compounds 1b, 1c, 1f, 1m, 
4f, 6, 31, 32, 33 and 34 are mutagenic (score 1) whereas the other compounds are non-mutagenic 
(score 2). The last parameter of pkCSM is hepatotoxic. There are 22 hepatotoxic compounds (score 
1) and 22 non-hepatotoxic compounds (score 2). 
At the Ames test endpoint of PreADMET, there are 14 mutagenic compounds (score 1) and 
30 other compounds are non-mutagenic compounds (score 2). The positive test results on Ames 
test indicate that the compound is mutagenic and has the possibility as carcinogenic. In the 
prediction of carcinogenicity in rat produced 11 carcinogenic positive compounds (score 1) and 33 
other compounds are negative carcinogenic (score 2). While in the prediction of carcinogenicity in 
mice, all of compounds are not carcinogenicity (score 2). 
In the study of Kuroiwa et al. (2015) obtained compounds 14, 16, 17, 19 and 31 which have 
the best activity with IC50 0.053 μM, 0.038 μM, 0.027 μM, 0.058 μM and 0.035 μM on cell line 
A549 (lung). The results of the toxicity prediction showed the five compounds having the lowest 
toxicity (largest scores), i.e. compounds 1j, 5, 14, 16 and 19. Compound 31 was not selected 
because of hepatotoxic, non-genotoxic and mutagenic carcinogens. While the compound 17 was 
not selected because of hepatotoxic. Compounds 1j, 5, 14, 16 and 19 are negative genotoxic 
carcinogens and non-genotoxic carcinogens, in vitro mutagenicity (Ames test), hepatotoxicity, and 
carcinogenicity in mice and rat. The highest maximum daily dose value among the five compounds 
is compound 1j, that is 3.034 mg/kg/day while the highest LD50 value is compound 16, that is 2.642 
mol/kg. 
Based on in vitro test results Kuroiwa et al. (2015) compounds 1j, 5, 14, 16 and 19 have IC50 
values of 20 μM, 1.8 μM, 0.053 μM, 0.038 μM and 0.058 μM. The compound with smaller IC50 is 
a compound that has higher activity as anticancer. Compounds 1j and 5 are not selected because 
they have a lower activity value compared to the other three compounds. Compounds that have 
small IC50 values with low toxicity effects, i.e. compounds 14, 16 and 19. 
 
CONCLUSION  
In the toxicity prediction of 1-phenyl-1-(quinazolin-4-yl) ethanol compounds using Toxtree, 
pkCSM and preADMET, three anticancer compounds have the highest activity in A549 cell (lung) 
and lowest toxicity i.e. compounds 14, 16 and 19. Compound 14 has IC50 of 0.053 μM and toxicity 
score of 21.886. Compound 16 has IC50 of 0.038 μM and toxicity score of 22.073. Meanwhile, 
compound 19 has IC50 of 0.058 μM and toxicity score of 21.692. 
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